Circulating Cell Biomarkers in Pulmonary Arterial Hypertension: Relationship with Clinical Heterogeneity and Therapeutic Response.
Olga Tura CeideIsabel BlancoJéssica Garcia-LucioRoberto Del PozoAgustín Roberto GarcíaElisabet FerrerIsabel CrespoDiego A Rodríguez-ChiaradiaCarmen Pilar Simeon-AznarManuel López-MeseguerClara Martín-OntiyueloVíctor I PeinadoJoan Albert BarberàPublished in: Cells (2021)
Patients with PAH showed higher numbers of EMVs and a lower percentage of PCs, compared with healthy controls. The EMV/PC ratio was increased in PAH patients, and in patients with SSc or HIV without PAH. After starting PAH therapy, individual changes in EMVs and PCs were variable, without significant differences being observed as a group. Conclusion: PAH patients present disturbed vascular homeostasis, reflected in changes in circulating EMV and PC levels, which are not restored with PAH targeted therapy. Combined measurement of circulating EMVs and PCs could be foreseen as a potential biomarker of endothelial dysfunction in PAH.
Keyphrases
- pulmonary arterial hypertension
- polycyclic aromatic hydrocarbons
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- single cell
- pulmonary hypertension
- stem cells
- pulmonary artery
- human immunodeficiency virus
- mesenchymal stem cells
- hiv aids
- south africa
- chemotherapy induced